{ "$and":[ { "$and": [ {"histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology"}, {"prostate cancer progression on androgen deprivation therapy or post bilateral orchiectomy within 6 months prior to randomization"}, {"current evidence of metastatic disease documented by bone scan or CT/MRI"}, { "$or": [ {"abiraterone-na√Øve"}, {"received prior abiraterone acetate for mHSPC or mCRPC treatment for at least 4 weeks and not progressed while on treatment"}, {"received prior abiraterone acetate for mHSPC or mCRPC treatment and progressed after at least 8 weeks, 14 weeks if bone progression"} ] }, {"ongoing androgen deprivation with serum testosterone <50 ng/dL"}, {"receiving bone resorptive therapy on stable doses prior to randomization"}, { "$and": [ {"agree to refrain from donating sperm"}, { "$or": [ {"be abstinent"}, {"use a male condom"} ] } ] }, {"provided newly obtained biopsy from soft tissue not previously irradiated or bone biopsy if bone only or predominant disease"}, {"ECOG performance status of 0 or 1 assessed within 7 days of randomization"} ] }, { "$not": { "$or": [ {"known additional malignancy progressing or active treatment in last 3 years"}, {"active autoimmune disease that required systemic treatment in past 2 years"}, {"diagnosis of immunodeficiency or receiving chronic systemic steroid therapy"}, {"major surgery including local prostate intervention, excluding biopsy, within 28 days prior to randomization without adequate recovery"}, {"gastrointestinal disorder affecting absorption or unable to swallow tablets/capsules"}, {"active infection requiring systemic therapy"}, {"history of noninfectious pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease"}, {"known active HIV, HBV, or HCV infection"}, {"known active CNS metastases and/or carcinomatous meningitis"}, {"hypersensitivity to pembrolizumab or enzalutamide or any excipients"}, {"history of seizure or condition predisposing to seizure"}, {"loss of consciousness within 12 months of screening"}, {"hypotension or uncontrolled hypertension at screening visit"}, {"bradycardia on screening ECG"}, {"history of prostate cancer progression on ketoconazole"}, {"prior treatment with enzalutamide, apalutamide, darolutamide or CYP17 inhibitor other than abiraterone acetate"}, {"prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2 agents or agent with T-cell receptor interaction"}, {"prior treatment with radium or other therapeutic radiopharmaceuticals for prostate cancer"}, {"prior treatment with docetaxel or chemotherapy agent for mCRPC"}, {"prior anti-cancer monoclonal antibody prior to randomization"}, {"used herbal products with hormonal anti-prostate cancer activity or known to decrease PSA levels prior to randomization"}, {"received a live or live attenuated vaccine within 30 days prior to randomization"}, {"participating or participated in another investigational study within 4 weeks prior to study treatment"}, {""superscan" bone scan"}, {"expecting to conceive or father children within study duration through 90 days after last dose of enzalutamide"}, {"had allogenic tissue/solid organ transplant"} ] } } ] }